Biotechnology In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx (secukinumab) treatment response rates continued to improve beyond the primary endpoint analysis, said Swiss pharma giant Novartis , which today announced that the prestigious medical journal The Lancet has published long-term data from the pivotal SUNSHINE and SUNRISE trials evaluating Cosentyx in moderate-to-severe HS. 4 February 2023